Form 4: 2seventy bio Executive Sells Shares Under 10b5-1 Trading Plan

Jessica Snow, a Senior Vice President at 2seventy bio, sold 2,287 shares of common stock at an average price of $3.2328 per share, under a pre-arranged 10b5-1 trading plan.

Summary

• Jessica Snow, a Senior Vice President at 2seventy bio, executed a sale of 2,287 shares of the company's common stock.
• The transaction occurred on December 13, 2024.
• The shares were sold at a weighted average price of $3.2328 per share.
• The sale was conducted automatically under a pre-established Rule 10b5-1 trading plan.
• Following the transaction, Ms. Snow directly owns 153,479 shares of 2seventy bio stock.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of an insider stock sale under a pre-arranged plan, which is neither positive nor negative for the company's outlook.

Industry Context

This is a routine disclosure of an insider stock sale, which is common for executives of publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, such as those in the biotechnology sector like 2seventy bio.
• Similar filings are regularly seen from executives at companies like CRISPR Therapeutics, Beam Therapeutics, and Editas Medicine, all of which are in the gene editing and cell therapy space.
• These filings are a standard part of corporate governance and transparency, ensuring that insider transactions are disclosed to the public.

Stakeholder Impact

• The stock sale by an executive may have a minor impact on investor sentiment, but is unlikely to significantly affect the company's operations or long-term prospects.

Key Dates

Keywords

2seventy bio, insider trading, stock sale, Rule 10b5-1, Jessica Snow, executive transaction